Oruka Therapeutics (ORKA) Cash from Operations Growth (3y) (2013 - 2026)
Oruka Therapeutics (ORKA) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 34.32% |
| 10 | Oruka Therapeutics | 947.75 Mn | 116.60 Mn | - | -145.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -145.42% |
| Dec 31, 2025 | -147.35% |
| Sep 30, 2025 | -105.21% |
| Jun 30, 2025 | -106.67% |
| Mar 31, 2025 | -69.33% |
| Dec 31, 2024 | -56.10% |
| Sep 30, 2024 | -78.76% |
| Jun 30, 2024 | -43.68% |
| Mar 31, 2024 | 68.20% |
| Dec 31, 2023 | 29.35% |
| Sep 30, 2023 | 5.88% |
| Jun 30, 2023 | 12.67% |
| Mar 31, 2023 | 1.83% |
| Dec 31, 2022 | -8.86% |
| Sep 30, 2022 | -41.22% |
| Jun 30, 2022 | -30.13% |
| Mar 31, 2022 | -40.01% |
| Dec 31, 2021 | -54.44% |
| Sep 30, 2021 | -45.65% |
| Jun 30, 2021 | -18.18% |